Is this actionable now?

unknown. BIRAC issues biotechnology call windows; no universal rolling entitlement.

An Indian biotech company must propose accelerated, high-risk technology development with commercial potential and provide the required contribution and partners.

What burden and restrictions apply?

Milestone-based disbursement, utilisation certificates, technical reports, audits and loan/royalty obligations depend on the approved instrument. Approved biotech R&D and translation cost only; grant and loan components must be separated.

What evidence exists?

BIPP is BIRAC's company-led high-risk biotechnology partnership program. No comparable current application denominator, award count and acceptance rate are published.

Biotechnology Industry Partnership Programme

Project-specific grant, soft-loan or blended support for high-risk biotechnology development; current call determines amount and instrument · Biotechnology Industry Research Assistance Council

Biotechnology Industry Partnership Programme is a grant programme from Biotechnology Industry Research Assistance Council for Indian biotechnology companies undertaking high-risk, accelerated technology development with commercial potential Current lifecycle: unknown. Real economics: Project-specific grant, soft-loan or blended support for high-risk biotechnology development; current call determines amount and instrument.

Tier 3governmentindiabiotechgrant

Apply Official site Open in the live directory

Key facts

Funder	Biotechnology Industry Research Assistance Council
Amount	Project-specific grant, soft-loan or blended support for high-risk biotechnology development; current call determines amount and instrument
Decision time	No universal application-to-decision interval is published for the currently verified route.
Eligibility	An Indian biotech company must propose accelerated, high-risk technology development with commercial potential and provide the required contribution and partners.
Restrictions	Milestone-based disbursement, utilisation certificates, technical reports, audits and loan/royalty obligations depend on the approved instrument. Approved biotech R&D and translation cost only; grant and loan components must be separated.
Status	unknown

Always confirm on the official page before applying — dates and terms change.

Application process

Respond to a live BIPP call
Submit technical, commercial and financial proposal
Complete expert review and presentation
Negotiate grant/loan and milestones
Report cost, technology and commercialization progress

Background

Biotechnology Industry Research Assistance Council operates Biotechnology Industry Partnership Programme. This pass separates direct cash, repayable finance, credits, incentives and umbrella programs so later ranking does not compare unlike instruments. BIPP is BIRAC's company-led high-risk biotechnology partnership program.

How the application really works

Respond to a live BIPP call → Submit technical, commercial and financial proposal → Complete expert review and presentation → Negotiate grant/loan and milestones → Report cost, technology and commercialization progress

Tips

Show direct fit with biotechnology.
Show direct fit with health.
Show direct fit with agriculture.
Show direct fit with industrial biotechnology.

Watch out for

Current lifecycle is unknown.
Milestone-based disbursement, utilisation certificates, technical reports, audits and loan/royalty obligations depend on the approved instrument.
Approved biotech R&D and translation cost only; grant and loan components must be separated.

Track record

BIPP is BIRAC's company-led high-risk biotechnology partnership program.

No comparable current application denominator, award count and acceptance rate are published.

Frequently asked questions

Is this actionable now?: unknown. BIRAC issues biotechnology call windows; no universal rolling entitlement.
What is the real economic value?: Project-specific grant, soft-loan or blended support for high-risk biotechnology development; current call determines amount and instrument
Who is eligible?: An Indian biotech company must propose accelerated, high-risk technology development with commercial potential and provide the required contribution and partners.
How does selection work?: Respond to a live BIPP call; Submit technical, commercial and financial proposal; Complete expert review and presentation; Negotiate grant/loan and milestones; Report cost, technology and commercialization progress. No universal application-to-decision interval is published for the currently verified route.
What burden and restrictions apply?: Milestone-based disbursement, utilisation certificates, technical reports, audits and loan/royalty obligations depend on the approved instrument. Approved biotech R&D and translation cost only; grant and loan components must be separated.
What evidence exists?: BIPP is BIRAC's company-led high-risk biotechnology partnership program. No comparable current application denominator, award count and acceptance rate are published.

Sources

birac.nic.in/bipp.php — Official program, applicant, instrument and application route (checked 2026-08-10)